Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C, Franquin J C
Department of Radiotherapy, Institut Paoli-Calmettes, Cancer Center, Marseilles, France.
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):697-703. doi: 10.1016/s0360-3016(97)00076-x.
To evaluate the efficiency of Helium-Neon (He-Ne) laser in the prevention of oral mucositis induced by high dose chemoradiotherapy before autologous bone marrow transplantation (BMT).
Between 1993 and 1995, 30 consecutive patients receiving an autologous peripheral stem-cell or bone marrow transplant (BMT) after high dose chemoradiotherapy were randomized to possibly receive prophylactic laser to the oral mucosa after giving informed consent. Chemotherapy consisted of cyclophosphamide, 60 mg/kg intravenously (I.V.) on day (d)-5 and d-4 in 27 cases, or melphalan 140 mg/kg I.V. on d-4 in three cases. Total body irradiation (TBI) consisted of 12 Gy midplane dose in six fractions (4 Gy/day for three days). He-Ne laser (632.8 nm wavelength, power 60 mW) applications were performed daily from d-5 to d-1 on five anatomic sites of the oral mucosa. Oral examination was performed daily from d0 to d + 20. Mucositis was scored according to an oral exam guide with a 16 item scale of which four were assessed by the patients themselves. Mean daily self assessment scores for oral pain, ability to swallow and oral dryness were measured. A daily mucositis index (DMI) and a cumulative oral mucositis score (COMS) were established. Requirement for narcotics and parenteral nutrition was recorded.
The COMS was significantly reduced among laser treated (L+) patients (p = 0.04). The improvement of DMI in L+ patients was also statistically significant (p < 0.05) from d + 2 to d + 7. Occurrence and duration of grade III oral mucositis were reduced in L+ patients (p = 0.01). Laser applications reduced oral pain as assessed by patients (p = 0.05) and L+ patients required less morphine (p = 0.05). Xerostomia and ability to swallow were improved among the L+ patients (p = 0.005 and p = 0.01, respectively). Requirement for parenteral nutrition was not reduced (p = NS).
Helium-Neon laser treatment was well tolerated, feasible in all cases, and reduced high dose chemoradiotherapy-induced oral mucositis. Optimal laser treatment schedules still needs to be defined.
评估氦氖(He-Ne)激光在预防自体骨髓移植(BMT)前高剂量放化疗所致口腔黏膜炎方面的效果。
1993年至1995年期间,30例在高剂量放化疗后接受自体外周干细胞或骨髓移植(BMT)的连续患者,在获得知情同意后被随机分组,部分患者可能接受口腔黏膜预防性激光治疗。27例患者的化疗方案为在第(d)-5天和d-4天静脉注射(I.V.)环磷酰胺60mg/kg,3例患者在d-4天静脉注射马法兰140mg/kg。全身照射(TBI)的中平面剂量为12Gy,分6次给予(每天4Gy,共3天)。从d-5至d-1,每天在口腔黏膜的5个解剖部位进行He-Ne激光(波长632.8nm,功率60mW)照射。从d0至d + 20每天进行口腔检查。根据一份有16项指标的口腔检查指南对黏膜炎进行评分,其中4项由患者自行评估。测量口腔疼痛、吞咽能力和口腔干燥的每日平均自我评估得分。建立每日黏膜炎指数(DMI)和累积口腔黏膜炎评分(COMS)。记录麻醉药品需求和肠外营养需求。
激光治疗组(L+)患者的COMS显著降低(p = 0.04)。从d + 2至d + 7,L+患者DMI的改善也具有统计学意义(p < 0.05)。L+患者III级口腔黏膜炎的发生率和持续时间降低(p = 0.01)。激光照射减轻了患者评估的口腔疼痛(p = 0.05),L+患者所需吗啡较少(p = 0.05)。L+患者的口干和吞咽能力得到改善(分别为p = 0.005和p = 0.01)。肠外营养需求未降低(p = 无显著性差异)。
氦氖激光治疗耐受性良好,在所有病例中均可行,并可减轻高剂量放化疗所致的口腔黏膜炎。最佳激光治疗方案仍有待确定。